GLPwatch

The treatment of hidradenitis suppurativa with the glucagon-like peptide-1 agonist liraglutide.

Br J Dermatol · 2017

Last updated 2026-05-28

A single patient with hidradenitis suppurativa (HS), a skin condition linked to inflammation and obesity, was treated with the GLP-1 drug liraglutide. After treatment, the patient lost weight and showed improved control of their HS symptoms. This is the first reported case of liraglutide being used for HS.

AI summary of the abstract below.

JournalBr J Dermatol, 2017
Citations44
Relative citation ratio2.42
NIH percentile79
Molecules liraglutide

Abstract

Hidradenitis suppurativa (HS) is a cutaneous disease associated with systemic inflammation, obesity and metabolic syndrome. Effective treatment options are limited. The antidiabetic agents, incretins, have been used successfully to treat psoriasis - a disease also associated with metabolic syndrome. We report the use of liraglutide, a glucagon-like peptide-1 agonist, in a patient with HS, leading to subsequent weight loss and improvement in disease control. To our knowledge, this is the first report of liraglutide used in the treatment of HS.

Verbatim abstract via PubMed 27943236 ↗

Related research